Basic Information
| LncRNA/CircRNA Name | ANRASSF1 |
| Synonyms | RASSF1-AS1, ANRASSF1 |
| Region | GRCh38_3:50337511-50338300 |
| Ensemble | ENSG00000281358 |
| Refseq | NR_109831 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | RNA-seq, qPCR, RNAi, Western blot, RIP, ChIP, Cell proliferation assay etc. |
| Sample | cell lines (HeLa, MDA-MB-231, LNCaP and MCF-8) |
| Expression Pattern | up-regulated |
| Function Description | ANRASSF1 endogenous expression is higher in breast and prostate tumor cell lines compared with non-tumor, and an opposite pattern is observed for RASSF1A. ANRASSF1 ectopic overexpression reduces RASSF1A abundance and increases the proliferation of HeLa cells, whereas ANRASSF1 silencing causes the opposite effects. These changes in ANRASSF1 levels do not affect the RASSF1C isoform abundance. ANRASSF1 overexpression causes a marked increase in both PRC2 occupancy and histone H3K27me3 repressive marks, specifically at the RASSF1A promoter region. |
| Pubmed ID | 23990798 |
| Year | 2013 |
| Title | The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. |
External Links
| Links for ANRASSF1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |